Home Newsfeeds Chardan Capital Initiates Coverage On EyePoint Pharmaceuticals with Buy Rating, Announces Price Target of $21

Chardan Capital Initiates Coverage On EyePoint Pharmaceuticals with Buy Rating, Announces Price Target of $21

Chardan Capital analyst Daniil Gataulin initiates coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy rating and announces Price Target of $21.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Chardan Capital analyst Daniil Gataulin initiates coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy rating and announces Price Target of $21.

Nio Stock Is Trading Higher Tuesday: What’s Going On?

By Adam Eckert

December 26, 10:50 AM

NIO Inc (NYSE: NIO) shares are trading higher Tuesday after the company unveiled a new smart EV model over the weekend.

NIO

Delta, Air Canada Passengers Face Hard Decisions When Confronted With Bodily Fluids

By AJ Fabino

September 6, 11:55 AM

Passengers aboard flights on two leading airlines, Delta Air Lines, Inc. (NYSE: DAL) and Air Canada (OTCMKTS: ACDVF), were recently confronted with situations involving bodily fluids, leading to some real discomfort and tough ch

ACDVF

Kineta To Host KOL Event To Review New Data From VISTA-101 Clinical Trial Of KVA12123 In Patients With Advanced Solid Tumors On December 5, 2023

By Benzinga Newsdesk

November 28, 9:31 AM

Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will host a virtual KOL

Trump’s Newly Listed DJT ‘Doesn’t Deserve This Valuation,’ Says Expert: ‘In Any Other World…This Would Be A Penny Stock’

By Benzinga Neuro

March 27, 5:46 AM

The critique aligns with a broader discussion on the financial viability of Trump's latest business venture calling it "overhyped."

DJT

Chardan Capital Initiates Coverage On EyePoint Pharmaceuticals with Buy Rating, Announces Price Target of $21

Related Posts

Nio Stock Is Trading Higher Tuesday: What’s Going On?

Delta, Air Canada Passengers Face Hard Decisions When Confronted With Bodily Fluids

Kineta To Host KOL Event To Review New Data From VISTA-101 Clinical Trial Of KVA12123 In Patients With Advanced Solid Tumors On December 5, 2023

Trump’s Newly Listed DJT ‘Doesn’t Deserve This Valuation,’ Says Expert: ‘In Any Other World…This Would Be A Penny Stock’